Introduction
============

The role of high-dose chemotherapy in the adjuvant treatment of high-dose breast cancer has not been established. Results have been reported from six randomized studies with a symmetrical study design (Table [1](#T1){ref-type="table"}). All show a lower relapse rate in the high-dose arm, but in only one study was this result statistically significant.

###### 

Randomized studies evaluating the role of high-dose chemotherapy in high-risk breast cancer

  Author            Patients   Selection          Conventional arm   High-dose arm    RFS analysis
  ----------------- ---------- ------------------ ------------------ ---------------- ----------------------------------
  Rodenhuis \[1\]   885        4^+^nodes          5×FEC              4×FEC - CTC      HD better (*P*= 0.08)
  Peters \[2\]      785        10^+^nodes         4×CAF + ID-CPB     4×CAF + HD-CPB   No difference, HD fewer relapses
  Tallman \[3\]     540        10^+^nodes         6×CAF              6×CAF + CT       No difference, HD fewer relapses
  Roché             314        8^+^nodes          4×FEC              4×FEC + CMA      HD better (*P*= 0.002)
  Tokuda            97         10^+^nodes         6×CAF              6×CAF + CT       HD better (NS)
  Rodenhuis         81         Infraclav biopsy   4×FEC              4×FEC + CTC      No difference, HD less relapses

CAF, cyclophosphamide, doxorubicin, fluorouracil; CMA, cyclophosphamide, mitoxantrone and melphalan; CT, cyclophosphamide and thiotepa; CTC, cyclophosphamide, thiotepa and carboplatin; FEC, fluorouracil, epirubicin, cyclophosphamide; nodes, tumor-positive axillary lymph nodes; HD-CPB, high-dose cyclophosphamide, cisplatin and BCNU; ID-CPB, intermediate-dose cyclophosphamide, cisplatin and BCNU.

Methods
=======

Patients below 56 years of age who had undergone surgery for stage II or III breast cancer were eligible if they had at least four tumor-positive axillary lymph nodes. Patients in the conventional dose (CD) arm received five courses of FEC (fluorouracil 500 mg/m^2^, epirubicin 90 mg/m^2^and cyclophosphamide 500 mg/m^2^; every 3 weeks) followed by radiation therapy and tamoxifen. The high-dose (HD) arm was identical, except that high-dose chemotherapy (CTC \[cyclophosphamide 6 g/m^2^, thiotepa 480 mg/m^2^and carboplatin 1600 mg/m^2^\]) with peripheral blood progenitor cell reinfusion was given instead of the fifth FEC course.

Results
=======

Between August 1993 and July 1999, 885 patients with primary breast cancer and four or more tumor-positive lymph nodes were randomized in 10 Dutch centers in a study of high-dose chemotherapy. The results of this study at 57 months of follow-up have now been updated at 87 months. In a pathology review, 621 tumor samples were shown to be HER2/neu-negative (either 0+ at immunohistochemistry or negative at *in situ*hybridization). Patients with HER2/neu-negative disease had a 5-year RFS of 72% following HD and of 59% after CD (*P*= 0.002). Overall survival in the HD group was 78% at 5 years versus 71% for the CD group (*P*= 0.02). Young age and low malignancy grade were associated with a relative benefit for HD (tests for interactions: *P*= 0.04 and *P*= 0.0057, respectively). The treatment-related mortality in the high-dose chemotherapy arm was 1%. An equal number of second malignancies were observed in both arms.

Conclusion
==========

Although the subgroup analysis of HER2/neu-negative disease was not planned in the original protocol, these findings are consistent with findings from other studies \[[@B4]\]. The marked efficacy of HD therapy in HER2/neu-negative breast cancer may have been masked in this and in other studies by its disadvantage in the HER2/neu-positive group, which may have benefited from a higher dose of anthracycline-dose in the control arm. High-dose alkylating chemotherapy is a viable option for high-risk breast cancer patients with HER2/neu-negative disease.
